GlassRatner Acquired by TorQuest Partners, Reestablishes Itself as an Independent Brand
With a 24-year legacy of delivering high-value financial advisory solutions, GlassRatner has built a reputation for excellence in Restructuring, Turnaround Management & Bankruptcy Consulting; Forensic Accounting & Litigation Support; and Transaction Support Services—such as Due Diligence and Quality of Earnings Reviews. In recent years the firm has successfully expanded its reach into Engineering & Construction Consulting, Risk & Resilience Consulting and Executive Search & Interim Management.
'Our brand and culture remain as vibrant and dynamic as ever. We have one of the strongest teams in the industry and are well poised for continued growth. We are well organized, well financed and committed to our clients. Over the past 24 years, we've been a trusted partner for top law firms, lenders, and private equity investors, tackling some of the most complex and high stakes matters. With approximately 200 team members and a dozen locations I feel like we are just getting started,' said Ian Ratner, CEO and co-founder.
Justin Catalano, a Partner at TorQuest said, 'We are excited to be partnering on this investment with Ian and the GlassRatner team. GlassRatner is an attractive business with significant growth potential and a strong reputation for service excellence. We look forward to supporting their continued growth in this next chapter.' GlassRatner will be the third platform investment for TorQuest Partners Fund VI, a C$2.3 billion fund.
GlassRatner expanded into Canada in 2023 with the acquisition of the commercial group of Farber Financial, which has been operating as B. Riley Farber Advisory Inc. ('B. Riley Faber'). Going forward, the Canadian operations will adopt the unified GlassRatner brand. Together with its office in Mexico City and extensive coverage across the United States, GlassRatner offers seamless advisory services across North America and globally through its partnership with BTG Global Advisory.
From an industry perspective, GlassRatner also brings deep expertise through both its dedicated Real Estate Services and Engineering & Construction Consulting practices, ensuring specialized knowledge where it really matters. The firm has also established a portfolio of credentials in sectors including HealthCare, Financial Services & Insurance, Automotive (both Manufacturing and Auto Dealerships), General Manufacturing, Energy, Retail, Food & Beverage, Hospitality, Government, and Non-Profits.
'Our firm continues to be a terrific platform for our team members. Our culture is rooted in collaboration, collegiality, and authenticity,' said Ratner. 'We are attracting some of the best and brightest in the industry and are committed to expanding our team aggressively to meet growing client demand.'
GlassRatner's award-winning team has consistently earned recognition across multiple industry publications and organizations, cementing our position as a leader in restructuring, litigation consulting, forensics, and expert witness services. We have been honored with accolades from Global M&A Network's Turnaround Atlas Awards, The Daily Report, The M&A Advisor's Annual Turnaround Awards, and The National Law Journal.
About GlassRatner
GlassRatner Advisory & Capital Group, LLC and B. Riley Farber Advisory Inc. (collectively 'GlassRatner') is a North American financial advisory services firm providing clarity to complex business challenges and board level agenda items.
GlassRatner provides a unique continuum of high value financial advisory services to attorneys and their clients, lenders, private equity investors, and companies of all types—across the US, Canada, and Mexico. Our team of seasoned professionals, with deep industry expertise, provide sophisticated solutions in a transparent, independent and collegial manner, putting clients and their success first.
Our advisory services are a unique mix of professional services including restructuring & turnaround management; forensic accounting, litigation support; engineering & construction consulting; risk & resilience consulting; transaction support services including due diligence and quality of earnings reviews, executive search and interim management solutions, and real estate services. To learn more about GlassRatner, please visit www.glassratner.com
About TorQuest Partners
Founded in 2002, TorQuest Partners is a Canadian-based manager of private equity funds. With more than C$5.0 billion of equity capital under management, TorQuest is currently investing from TorQuest Partners Fund VI, a C$2.3 billion fund that held its final closing in December 2023 and completed its first investment in July 2024. TorQuest invests in middle market companies and works in close partnership with management to build value. To learn more about TorQuest, please visit www.torquest.com
Minela Sejdin GlassRatner 470-346-6822 [email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
32 minutes ago
- Business Upturn
GENIUS Act: The Catalyst for Trillions in Real-World Asset Tokenization with Deal Box and OroBit
San Diego, CA , Aug. 04, 2025 (GLOBE NEWSWIRE) — The passage of the landmark GENIUS Act marks a defining moment for the digital asset industry, further opening the door for mainstream adoption of real-world asset (RWA) tokenization, an industry expected to surpass $16 trillion this decade. Positioned at the heart of this financial evolution are fintech pioneer Thomas Carter's Deal Box and blockchain infrastructure innovator OroBit—two firms uniquely prepared to harness these converging opportunities. The GENIUS Act provides explicit regulatory guidelines for stablecoins and digital assets, clarifying critical elements such as reserve requirements (mandating 100% reserves in USD or short-term Treasuries), monthly audits, AML compliance, and dual federal and state licensing oversight. These clear guidelines remove major uncertainties that have long constrained institutional participation, signaling an era of greater investor confidence and market stability. This regulatory clarity arrives during an unprecedented uptick in institutional interest in cryptocurrency markets, notably driven by recent Bitcoin ETF approvals and increasing investment from banks and asset managers. The crypto market capitalization has surged past $4 trillion, reflecting robust, ongoing confidence from institutional treasuries. Thomas Carter, CEO and founder of Deal Box, emphasized the strategic importance of this regulatory development: 'The GENIUS Act couldn't be better timed. The clarity and legitimacy it provides aligns perfectly with growing institutional confidence in digital assets. This convergence creates precisely the environment we've anticipated, enabling Deal Box and our partners at OroBit to rapidly scale tokenization solutions, especially in private equity and traditionally illiquid markets.' Since its inception in 2016, Deal Box has actively championed the tokenization of private equity and alternative assets, offering investors unprecedented access, transparency, and liquidity. Deal Box is also at the forefront of AI technology, partnering with Wild Mouse, an Australian enterprise software company, which has developed a globally unique platform designed to ingest, analyze, and act on unstructured data at scale, offering transformative potential for companies like OroBit. OroBit complements this vision with their sophisticated Smart Contract Layer (SCL), a robust blockchain protocol built on Bitcoin, securely automating tokenization, ownership management, and compliance processes, providing infrastructure for mainstream adoption. By leveraging Bitcoin—the largest and most secure blockchain—OroBit is strategically positioned to capture substantial value as the Bitcoin network itself experiences historic growth and adoption. Warwick Powell, Chairman of OroBit, highlighted the transformative impact of this legislation and strategic alignment: 'The GENIUS Act directly validates the infrastructure we've developed, clearing the path for institutional-grade adoption at a scale previously unimaginable. Alongside Deal Box, we're positioned to become the new standard-bearer for secure, compliant, and efficient tokenized financial products.' The unified ecosystem they have crafted, powered by an enterprise-grade AI platform, is redefining how private equity, real estate, art, and other high-value assets are owned, traded, and managed globally. The long-anticipated tokenization revolution is now underway. About Deal Box Deal Box is venture capital that fits your life. We bring institutional clarity to tokenized and traditional assets through credible AI structuring, Bitcoin-first token design, and packaging built for investor diligence. Structured for issuer-led offerings under Rule 506(c), Deal Box does not act as a broker-dealer or placement agent and receives no compensation tied to capital raised. contact: [email protected] About OroBit OroBit delivers secure, scalable Bitcoin Layer-2 solutions, enabling sophisticated smart-contract capabilities specifically tailored to institutional and private market asset tokenization. See for more information contact [email protected] Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Business Upturn
32 minutes ago
- Business Upturn
CYCLACEL PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DATA SHOWING THAT CANCER OF THE BILIARY TRACT IS SENSITIVE TO PLOGOSERTIB
– Biliary tract cancer (BTC) or cholangiocarcinoma is an aggressive tumor with poor prognosis – KUALA LUMPUR, Malaysia, Aug. 04, 2025 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; 'Cyclacel' or the 'Company'), a biopharmaceutical company developing innovative cancer medicines, highlighted a preclinical study from independent investigators titled, ' Evaluation of antitumor effects of plogosertib, PLK1 inhibitor in biliary tract cancer with BUBR1 as a potential biomarker ' in the journal, Cancer Research, previously reported in a poster at the American Association of Cancer Research 2025 annual meeting.1 The investigators found that several BTC cancer cell lines were sensitive to plogosertib both as monotherapy and in combinations. Consistently with its antimitotic mechanism of action, plogosertib promoted mitotic checkpoint complex (MCC) formation in prometaphase, which induced mitotic arrest resulting in apoptosis of BTC cells. The authors have also found that BUBR1, a critical mitotic checkpoint protein, may be useful as a biomarker to assess plogosertib's effectiveness. BTC cells with high BUBR1 expression were found to be more sensitive to plogosertib compared to those with low expression. The study concluded that BTC cells with high BUBR1 expression are sensitive to the PLK1 inhibitor plogosertib that demonstrate synergistic effects when combined with an ATR inhibitor, which suggest that targeting PLK1 could be an effective strategy for BTC treatment, especially with BUBR1 expression as a potential biomarker to inform optimal combination therapies. About Biliary Tract Cancer (BTC) BTC, also called cholangiocarcinoma, is a rare but aggressive cancer occurring in the biliary tract, a network of small tubes, or ducts, connecting the liver, gallbladder and small intestine. According to estimates from the National Cancer Institute's SEER database annual US incidence of BTC is 4.4 per 100,000. Prognosis for BTC patients is poor with 5-year overall survival of approximately 10–40% even after surgical tumor resection. BTC treatment strategies include chemotherapy, surgery, radiation and targeted medicines depending on location and stage. As these approaches are not curative, there is an urgent, unmet medical need to treat patients with relapsed, refractory and/or unresectable BTC. About Polo-like Kinase and Plogosertib Polo-like kinase 1 (PLK1) is a serine/threonine kinase that plays a central role in cell division or mitosis. PLK1 is an important regulator of the DNA damage cell cycle checkpoint, mitotic entry and exit, spindle formation and cytokinesis, or cell separation into daughter cells. In general, cancer cells, and in particular KRAS mutated and p53(-) cells, are very sensitive to PLK1 depletion. In contrast normal cells with intact cell cycle checkpoints are less sensitive. Pharmacological inhibition of PLK1 in cancer cells blocks proliferation by prolonged mitotic arrest and induces onset of apoptotic death of such cells. Plogosertib (formerly CYC140) is a novel, small molecule, selective and potent PLK1 inhibitor. It has demonstrated impressive efficacy in human tumor xenografts at nontoxic doses. Cyclacel's translational biology program supports the development of plogosertib in solid tumors and leukemias. Preclinical data from independent groups have shown that certain ARID1A- and/or SMARCA-mutated cancers, and cancers associated with DNAJ-PKAc fusions, may benefit from treatment with plogosertib. Additionally, recent data suggest that PLK1 inhibition may be effective in KRAS-mutated metastatic colorectal cancer. PLK1 overexpression correlates with poor patient prognosis in several tumors, including biliary tract, esophageal, fibrolamellar liver, gastric, leukemia, lung, ovarian, and squamous cell cancers, as well as MYC-amplified cancers. Initial dose escalation data from a Phase 1 clinical study of oral plogosertib suggest that the compound is well tolerated with no dose limiting toxicity observed in five dosing schedules. Clinical benefit was observed in patients with adenoid cystic, biliary tract, ovarian, and squamous cell sinus cancers. About Cyclacel Pharmaceuticals, Inc. Cyclacel is a clinical-stage, biopharmaceutical company developing innovative cancer medicines based on cell cycle and mitosis biology. The anti-mitotic program is evaluating plogosertib, a PLK1 inhibitor, in patients with both solid tumors and hematological malignancies. Cyclacel's strategy is to build a diversified biopharmaceutical business based on a pipeline of novel drug candidates addressing oncology and hematology indications. For additional information, please visit Forward-looking Statements This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended and the Safe Harbor provisions of the US Private Securities Litigation Reform Act of 1995, and encompasses all statements, other than statements of historical fact contained in this press release. These forward-looking statements can be identified by terminology such as 'may,' 'could,' 'will,' 'expects,' 'anticipates,' 'aims,' 'future,' 'intends,' 'plans,' 'believes,' 'estimates,' 'targets,' 'likely to', 'understands' and similar statements. These forward-looking statements are based on management's current expectations. However, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. These statements are neither promises nor guarantees but involve known and unknown risks, uncertainties and other important factors and circumstances that may cause Cyclacel's actual results, performance or achievements to be materially different from its expectations expressed or implied by the forward-looking statements, including conditions in the U.S. capital markets, negative global economic conditions, potential negative developments resulting from epidemics or natural disasters, other negative developments in Cyclacel's business or unfavorable legislative or regulatory developments. We caution you therefore against relying on these forward-looking statements, and we qualify all of our forward-looking statements by these cautionary statements. For a discussion of additional factors that may affect the outcome of such forward-looking statements, see our 2024 annual report on Form 10-K, and in particular the 'Risk Factors' section, as well as the other documents filed with or furnished to the SEC by Cyclacel from time to time. Copies of these filings are available online from the SEC at or on the SEC Filings section of our Investor Relations website at These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. These forward-looking statements should not be relied upon as representing Cyclacel's views as of any date subsequent to the date of this press release. All forward-looking statements in this press release are based on information currently available to Cyclacel, and Cyclacel and its authorized representatives assume no obligation to update these forward-looking statements in light of new information or future events. Accordingly, undue reliance should not be placed upon the forward-looking statements. Contact Cyclacel Pharmaceuticals, Inc. Email: [email protected] © Copyright 2025 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel logo and Cyclacel® are trademarks of Cyclacel Pharmaceuticals, Inc. SOURCE: Cyclacel Pharmaceuticals, Inc. 1 Yoojin Jeong, Yoojin Jeong, et al, Abstract 5406: Evaluation of antitumor effects of plogosertib, PLK1 inhibitor in biliary tract cancer with BUBR1 as a potential biomarker, Cancer Res (2025) 85 (8 Supplement 1): 5406. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Business Upturn
32 minutes ago
- Business Upturn
United Rotorcraft Secures First International FIREHAWK® Contract with Colombian Air Force
ENGLEWOOD, CO, Aug. 04, 2025 (GLOBE NEWSWIRE) — United Rotorcraft, a division of Air Methods LLC, is proud to announce its first international contract for the FIREHAWK® helicopter, following a groundbreaking agreement with the Colombian Air Force. This contract marks a significant milestone in the global recognition of the FIREHAWK as a premier aerial firefighting and emergency response asset. Under this agreement, United Rotorcraft will be converting 2 legacy UH-60L Black Hawks to the FIREHAWK configuration. This includes the installation of United Rotorcraft's exclusive high landing gear, a 1,000-gallon DART Aerospace composite belly tank, and an advanced avionics suite designed to improve situational awareness during mission-critical operations. Colombia has a long-standing legacy of leadership in Black Hawk operations. The Colombian Air Force was the first international operator of the Black Hawk and the first to deploy an armed fleet. The Colombian National Police were the first law enforcement agency to operate the Black Hawk. With this new acquisition, the Colombian Air Force becomes the first international operator of the FIREHAWK helicopter. 'Colombia has operated Black Hawk helicopters for 37 years, giving us highly experienced pilots and crewmembers trained specifically for firefighting missions,' said General Luis Carlos Córdoba, Commander of the Colombian Air Force. 'This ensures the successful deployment and operation of the FIREHAWK in our country.' According to official data reported by WRadio on July 11, 2025, more than 7,300 wildfires were recorded in Colombia last year, affecting approximately 290,000 hectares (716,000 acres). 'Wildfires have become a global phenomenon and a growing concern for communities across the world,' said Larry Alexandre, President of United Rotorcraft. 'We are honored to introduce the FIREHAWK's unmatched capabilities to our first international customer and to deliver this life-saving asset to the Colombian Air Force as they strengthen their capacity to protect land, wildlife, and communities from the escalating threat of wildfires. The FIREHAWK has become a benchmark for public agencies across the US Western States, and we are convinced it will become equally popular and effective beyond the US borders, starting with Colombia' This effort was the result of a unique collaboration between the Colombian National Unit for Disaster Risk Management (UNGRD), the Colombian Air Force (FAC), and the Colombian Aeronautical Industry Corporation (CIAC). 'The FIREHAWK is the world's most powerful aerial firefighting platform,' said Carlos Carrillo, Director of UNGRD. 'This technology will enhance emergency response capabilities in moorlands, jungles, savannas, coastal regions, and other hard-to-reach areas.' United Rotorcraft is dedicated to delivering cutting-edge aerial firefighting capabilities through innovation and global collaboration. The introduction of the FIREHAWK into international service represents a major advancement in global wildfire response efforts. ### About United Rotorcraft United Rotorcraft is a leader in mission-critical helicopter completions and modifications, known for designing, manufacturing, and integrating mission-critical equipment for emergency response helicopters. With 30 years of experience in aviation solutions, the company specializes in custom completions for aerial firefighting, search and rescue, and HEMS. Attachment United Rotorcraft Announces First International Contract Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
